FIELD: medicine, pharmaceuticals.
SUBSTANCE: disclosed is application of dipeptidyl peptidase inhibitors (DPIV-inhibitors) particularly isoleucyl-tiazolidine as active ingredient of pharmaceutical hypotensive composition for mammalian suffering from diabetes. Disclosed is stabilizing of systolic blood pressure in diabetic fats and lowering levels thereof from 170 mmHg (control animals without isoleucyl-tiazolidine) to 150 mmHg.
EFFECT: new dipeptidyl peptidase inhibitors useful in pharmaceutical hypotensive composition.
9 cl, 9 dwg, 11 tbl, 20 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND THEIR USING AS ANTICANCER AGENTS | 2002 |
|
RU2299066C2 |
| EFFECTORS OF DIPEPTIDYL PEPTIDASE IV | 1999 |
|
RU2309161C2 |
| METHOD FOR IMPROVING SIGNAL TRANSFER IN ISLETS OF LANGERHANS IN DIABETES MELLITUS AND IN ITS PROPHYLAXIS | 2001 |
|
RU2261096C2 |
| NEW ANTI-DIABETIC AGENTS | 2000 |
|
RU2265012C2 |
| AGENT OF PEPTIDE STRUCTURE, INHIBITING DIPEPTIDYL PEPTIDASE-4, AND PHARMACEUTICAL COMPOSITION BASED THEREON | 2015 |
|
RU2589258C1 |
| ACYLATED INSULIN ANALOGUES STABILISED WITH RESPECT TO PROTEASES | 2009 |
|
RU2571857C2 |
| APPLICATION OF DIPEPTIDYLPEPTIDASE IV INHIBITORS | 2004 |
|
RU2385723C2 |
| PRODRUG COMPOSITIONS WITH HIGH DEGREE OF PENETRATION BASED ON PEPTIDES AND RELATED COMPOUNDS | 2010 |
|
RU2627065C2 |
| EXENATIDE ANALOGUE | 2020 |
|
RU2823623C1 |
| PROTEASE-RESISTANT INSULIN ANALOGUES | 2007 |
|
RU2524150C2 |
